Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Dr. McKinney Discusses the Watch-and-Wait Approach in MCL

May 29th 2019

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma.

Dr. Wang Discusses the Future of Treatment in MCL

May 24th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

MCL Landscape Rapidly Evolving With Promising Approaches on Horizon

May 24th 2019

Ann S. LaCasce, MD, MMSc, highlights recent progress made in MCL, exciting approaches under investigation, and provides insight into where future research should focus.

Small Molecule Shows Marked Activity Against Ibrutinib-Resistant MCL

May 17th 2019

Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.

Dr. Fenske on the Future of Daratumumab in MCL

May 7th 2019

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

MCL Treatment Paradigm Expands With Novel Combos

May 1st 2019

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.

Clinical Outcomes Consistent in MCL Irrespective of Induction Regimen

April 25th 2019

Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma, irrespective of the chemoimmunotherapy induction regimen that was administered.

Dr. Shah on Ongoing Trials in MCL

April 23rd 2019

Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).

Dr. LaCasce Discusses the Future of MCL Treatment

April 22nd 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the future of mantle cell lymphoma treatment.

Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL

April 21st 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).

Dr. Shah on Challenges With Developing MCL Clinical Trials

April 19th 2019

Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.

Dr. Goy on Treatment Considerations in MCL

April 18th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Clinical Factors in MCL Successful in Guiding Watch-and-Wait Strategy

April 18th 2019

Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.

Dr. LaCasce on Key Advances in the MCL Paradigm

April 18th 2019

MCL Armamentarium Expands, But Quest Continues for Curative Approaches

April 17th 2019

Ann S. LaCasce, MD, MMSc, highlights the therapeutic progress in the treatment of patients with mantle cell lymphoma , key remaining challenges, and where future research is headed.

Dr. Shah on Overcoming Resistance to BTK Inhibitors in MCL

April 17th 2019

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Goy on Treatment Options for Patients With MCL

April 11th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL).

Dr. Lossos on Research Questions in MCL

April 5th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research questions in the field of mantle cell lymphoma (MCL).

Dr. Goy on Future Treatment Approaches in MCL

April 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma.